ASX:BD1 BARD1 Life Sciences (BD1) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BARD1 Life Sciences Stock (ASX:BD1) 30 days 90 days 365 days Advanced Chart Get BARD1 Life Sciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume801,545 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia. Read More Receive BD1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address BD1 Stock News HeadlinesLife KitMarch 14, 2023 | npr.orgNTake AstraZeneca’s warning seriously. The UK is missing out in life sciencesFebruary 12, 2023 | theguardian.comInvest where Wall Street isn’t looking—yetSome investors quietly turn a few thousand dollars into hundreds of thousands—before a company ever goes public. Sure… some of that is luck. But it’s not dumb luck. It’s knowing where to look, and even more importantly, which deals to avoid.July 25 at 2:00 AM | Darwin (Ad)See a Real-Life 'Terminator' Robot Turn Into Liquid to Bust Out of a CageFebruary 5, 2023 | cnet.comBay Area's biggest life science stock winners and losers in 2022January 14, 2023 | bizjournals.comJUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIAJanuary 13, 2023 | finance.yahoo.comSELLAS Life Sciences Group Shares Drop 40% on Clinical Trial UpdateNovember 16, 2022 | marketwatch.comQuantori is building an app development platform focused on life sciencesOctober 13, 2022 | techcrunch.comTSee More Headlines BD1 Stock Analysis - Frequently Asked Questions What other stocks do shareholders of BARD1 Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that BARD1 Life Sciences investors own include Vulcan Energy Resources (VUL), Splitit Payments (SPT), Meta Platforms (META), Lake Resources (LKE), Kalium Lakes (KLL) and Collins Foods (CKF). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:BD1 CIKN/A Webwww.bard1.com Phone61 8 9381 9550FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.35 Current Ratio3.87 Quick Ratio3.58 Sales & Book Value Annual SalesA$1.27 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.33 Book ValueA$0.36 per share Price / BookN/AMiscellaneous Outstanding Shares92,018,704Free FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (ASX:BD1) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BARD1 Life Sciences Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share BARD1 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
